DINAMIKA MINERAL'NOY PLOTNOSTI KOSTI, MARKEROV KOSTNOGO OBMENA I KAChESTVA ZhIZNI PATsIENTOV S ENDOGENNYM GIPERKORTITsIZMOM POSLE DOSTIZhENIYa REMISSII ENDOGENNOGO GIPERKORTITsIZMA

This study estimates the recovery of bone mineral density (BMD), markers of bone remodeling and quality of life in patients with endogenous Cushing’s syndrome (CS) after 12 months of achieving remission. Materials and methods: 21 patients with CS were prospectively evaluated at active stage of the disease and after being in a full remission (substitutional therapy with hydrocortisone or normal 24 hours urinary free cortisol (24h UFC) and late-night cortisol) during 12 months.A thoracic and lumbar X-ray was performed to reveal vertebral fractures. Bone mineral density (BMD) was measured by DXA ((Prodigy, Lunar, GE, USA). The level of 24h UFC was measured on a VitrosECi. Late-night serum cortisol and markers of bone remodeling were assayed by ECLIA Cobas e601 Roche. Patients fulfilled EQ-5D, ECOS-16 questionnaires and performed "up-and-go ”, "tandem ” and "chair-rising ” tests. Results: Among enrolled patients 17 (80%) were females and 4 (20%) - males; median of age (Q25-Q75) - 41 (33-49) years old; in 10 cases (48%) low traumatic fractures were diagnosed: 7 patients suffered from vertebral fractures; in 3 cases - ribs fractures. After the achieving remission no new fractures were registered and significant improvement in Z-score was reviled at all regions: L1-L4 -1,8 [-2,6; -0.5] at active stage vs -1,2 [-2,2; -0.5] after 12 months of remission (p=0.05); Neck Z-score -0,9 [-1,7; - 0,8] vs -0,7 [-1,6; -0,3], (p=0,003). The level of both bone metabolism markers increased: osteocalcin from 8,2 (6,912,0) to 22,7 (12,1-36,5) ng/ml (p=0,01) and CTx from 0,35 (0,22-0,63) to 0,7(0,28-1,05) ng/ml (p=0,01); whereas 24hUFC decreased from 1449 (926,4-2371) nmol/24h to 66,4(54,2-76,4) nmol/24h (p=0,01). The quality of life significantly improved at all dimensions if measured by ECOS-16. According to the EQ-5D patients suffered less from pain 1,35 (0,49) vs 1,12 (0,34), (p=0,04) and reported the improvement in their health (visual analogue scale) from 49 (18,9) to 68 (10,9), (p=0,004), but did not differ in others dimensions. Although 100% of patients admitted the improvement in their functional ability, the difference in functional tests did not reach statistical significance. Conclusions: Achieving the remission of CS improves BMD and quality of life in patients with CS. However, longer time is needed for full recovery, including the functional performance.

1. Toth M., Grossman A., Glucocorticoid-induced osteoporosis: lessons from Cushing's syndrome; Clin Endocrinol (Oxf). 2013 Mar 2. doi: 10.1111/cen.12189.

2. Lekva T., Ueland T., B0yum H., Evang J.A., Godang K., Bollerslev J. TXNIP is highly regulated in bone biopsies from patients with endogenous Cushing's syndrome and related to bone turnover. Eur J Endocrinol. 2012 Jun; 166(6): 1039-48. doi: 10.1530/EJE-11-1082. Epub 2012 Mar 26.

3. Belaya Z.E., Rozhinskaya L.Y., Solodovnikov A.G., Dragunova N.V., Melnichenko G.A.: Glucocorticoid -inducedosteoporosis: fracture sand bone remodeling inpatients with endogenous Cushing’s syndrome. Series: Endocrinology Research and Clinica lDevelopments. Online Book, Published by Nova Science Publishers, Inc New-York, 2013, 55 pp; ISBN: 978-1-62948-341-2.

4. Драгунова Н.В., Белая Ж.Е., Рожинская Л.Я.: Состояние костно-мышечной системы при эндогенном гиперкортицизме. Остеопороз и Остеопатии 2012; 3: с. 18-24.

5. Белая Ж.Е., Рожинская Л.Я., Драгунова Н.В., Солодовников А.Г., Ильин А.В., Дзеранова Л.К., Мельниченко Г.А., Дедов И.И. Сывороточные концентрации белков регуляторов остеобластогенеза и остеокластогенеза у пациентов с эндогенным гиперкортицизмом. Остеопороз и остеопатии 2012; 2: с. 3-8.

6. Белая Ж.Е., Драгунова Н.В., Рожинская Л.Я., Мельниченко Г.А., Дзеранова Л.К., Дедов И.И. Низкотравматичные переломы у пациентов с эндогенным гиперкортицизмом. Предикторы и факторы риска, влияние на качество жизни. Остеопороз и остеопатии 2013; 1: с. 7-13.

7. Рожинская Л.Я. Остеопенический синдром при заболеваниях эндокринной системы и постменопаузальный остеопороз: патогенетические аспекты, диагностика и лечение. Дисс.. Док. Мед наук; Москва 2002.

8. Kanis J.A., Johansson H., Oden A., Johnell O., de Laet C., Melton J., Tenenhouse A., Reeve J., Silman A.J., Pols H.A.P., Eisman J.A., McCloskey E.V., Mellsrom D.: A meta-analysis of prior corticosteroid use and fracture risk. J Bone and Mineral Research 2004; Vol. 19: p. 893-899.

9. Tauchmaonova L., Pivonello R., Di Somma C., Rossi R., De Martino M.C., Camera L., Klain M., Salvatore M., Lombardi G., Colao A.: Bone Demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J. Clin Endocrinol. Metab 2006; Vol. 91: p. 1779-1784.

10. Kaltsas G., Makras P. Skeletal diseases in Cushing's syndrome: osteoporosis versus arthropathy. Neuroendocrinology 2010; 92 Suppl 1: 60-4. doi: 10.1159/000314298. Epub 2010 Sep 10.

11. Григорьев А.Ю. Нейрохирургическое лечение пациентов с болезнью Иценко-Кушинга и акромегалией. Дисс.. Док. Мед наук 2011: с. 257.

12. Lindsay J.R., Nansel T., Baid S., Gumovski J., Nieman L.K. Long-term impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J. Clin. Endocrinol. Metab 2006; Vol. 91: p. 447-453.

13. Heald A.H., Ghosh S., Bray S., Gibson C., Anderson S.G., Buckler H., Fowler H.L. Long-term negative impact on quality of life in patients with successfully treated Cushing’s disease. Clin Endocrinol 2004; Vol. 61: p. 458-465.

14. Pivonello R., De Martino M.C., De Leo M., Tauchmanova L., Facciano A., Lombardi G., Colao A. Cushing’s syndrome: Aftermath of the cure. Arq Bras Endocrinol Metab 2007; Vol. 51: p. 1381-1391.

15. Белая Ж.Е., Ильин А.В., Мельниченко Г.А., Рожинская Л.Я., Драгунова Н.В., Дзеранова Л.К., Огнева Н.А., Бутрова С.А., Трошина Е.А., Колесникова Г.С., Дедов И.И.: Автоматизированный электрохемилюминисцентный метод определения кортизола в слюне для диагностики эндогенного гиперкортицизма среди пациентов с ожирением. Ожирение и метаболизм 2011; том 27: 2: с. 56-63.

16. Balestroni G., Bertolotti G., EuroQol-5D (EQ-5D): an instrument for measuring quality of life. Monaldi Arch Chest Dis 2012 Sep; 78(3): p.155-159.

17. Rabin R., Oemar M., Oppe M.: EQ-5D-3LU ser Guide: Basic information on how to use the EQ-5D-3L instrument. Version 4.0 April 2011.

18. Abourzazzak F.E., Allali F., Rostom S., Hmamouchi I., Ichchou L., Mansouri L.E., Bennani L., Khazzani H., Abouqal R., Hajjaj-Hassouni N.: Factors influencing quality of life in Moroccan postmenopausal women with osteoporotic vertebral fracture assessed by ECOS 16 questionnaire. Health and quality of life outcomes 2009; Vol. 7: p. 23-31.

19. Badia X., Diez-Perez A., Lahoz R., Lizan L., Nogues X., Iborra J.: The ECOS-16 questionnaire for the evaluation of health related quality of life in post-menopausal women with osteoporosis. Health and quality of life outcomes 2004; Vol. 2: p. 41-52;

20. Salaffi F., Malavolta N., Cimmino M.A., Di Matteo L., Scendoni P., Carotti M., Stancati A., Mule R., Fringato M., Gutierrez M., Grassi W., Italian Multicentre Osteoporotic Fracture (MOF) Study Group.: Validity and reliability of the Italian version of the ECOS-16 questionnaire in postmenopausal women with prevalent vertebral fractures due to osteoporosis. Clin Exp Rheumatol 2007; Vol. 25: p. 390-403.

21. Genant H.K., Wu C.Y., van Kujik C., Nevitt M.C. Vertebral fracture assessment using a semiquantative technique. J. Bone Miner Res 1993; 8: p. 1137-1148.

22. Podsialdo D., et al. J. Am. Geriatr Soc, 1991, Vol. 39 (2), pp. 142-14834,

23. Mathias S., etal. Arch Phys Med Rehabil, 1986, Vol. 67, pp. 387-389

24. Runge M., Rehfeld G., Resnicek E.: Balance training and exercise in geriatric patients. J. Musculoskel Neuronal Interact 2000; Vol. 1: p. 54-58.

25. Gill T.M., Williams C.S., Tinetti M.E.: Assessing risk for the onset of functional dependence among older adults: the role of physical performance. J. American Geriatr Soc 1995; Vol. 43: p. 603-609.

26. Williams C.S., et al. J. American Geriatr Soc 1995; Vol. 43: p. 603-609 Guralnik J.M., et all. New England J. Medicine, 1995, Vol. 332, pp. 556-561.

27. Kristo C., Jemtland R., Ueland T., Godang K., Bollerslev J. Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing’s syndrome: a prospective long-term study. European J. Endocrinology 2006; Vol. 154: p. 109-118.

28. Futo L., Toke J., Patocs A., Szappanos A., et all. Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing’s syndrome. J. Osteoporosis Int 2008; Vol. 19: p. 941-949.

29. Barahona M., Sucunza N., Resmini E., et all. Deletorious Effects of Glucocorticoid replacement on bone in women after long-term remission of Cushing’s syndrome. J. of Bone Miner. Res. 2009, Vol. 24, pp. 1841-1846.

30. Vestergaard P., Lindholm J., Jorgensen J., et all. Increased risk of osteoporotic fractures in patients with Cushing’s syndrome. European J. Endocrinol 2002; Vol. 146: p. 51-56.

31. Ammini A.C., Tandon N., Gupta N., et all. Etiology and clinical profile of patients with Cushing's syndrome: A single center experience. Indian J Endocrinol Metab 2014 Jan; 18(1): 99-105. doi: 10.4103/2230-8210.126586.

32. Ragnarsson O., Johannsson G. Cushing's syndrome: a structured short- and long-term management plan for patients in remission. Eur J Endocrinol 2013 Oct 4; 169(5): R139-152. doi: 10.1530/EJE-13-0534. Print 2013 Nov.